VASO is gaining from higher equipment deliveries, growing deferred commissions and a sharper healthcare focus, though partner dependence and margin pressures persist.
VASO is benefiting from stronger healthcare sales, improved profitability and a streamlined portfolio, but GEHC reliance and market pressures remain challenges.
VASO's first-quarter 2026 revenues dip after its healthcare IT divestiture, but losses narrow and deferred revenue kept climbing.
| Consumer Finance Industry | Financials Sector | Jun Ma CEO | OTC PINK Exchange | 92233F102 CUSIP |
| US Country | 282 Employees | - Last Dividend | 16 Dec 1991 Last Split | 24 Oct 1988 IPO Date |
Vaso Corporation, initially known as Vasomedical, Inc. before rebranding in November 2016, is a multifaceted company deeply embedded in the healthcare sector. This conglomerate has a diverse operational footprint spanning the United States and various international markets, focusing on healthcare equipment and information technology industries. Established in 1987 and based in Plainview, New York, Vaso Corporation orchestrates its business operations through three main segments: IT, Professional Sales Service, and Equipment. These segments collaboratively contribute to the company’s dedication to enhancing healthcare delivery through innovative technology and services.
Vaso Corporation's diverse array of products and services is categorized into three primary segments, each serving a unique role within the healthcare industry: